Brainstorm Cell Therapeutics (NASDAQ:BCLI) Downgraded by Maxim Group to “Hold”

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was downgraded by investment analysts at Maxim Group from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday, July 23rd, MarketBeat Ratings reports.

Separately, Wall Street Zen upgraded shares of Brainstorm Cell Therapeutics to a “sell” rating in a research note on Saturday, June 14th.

Brainstorm Cell Therapeutics Stock Performance

Shares of NASDAQ:BCLI traded down $0.02 during midday trading on Wednesday, hitting $0.73. The company’s stock had a trading volume of 84,653 shares, compared to its average volume of 676,769. The stock has a market capitalization of $8.00 million, a price-to-earnings ratio of -0.22 and a beta of 0.22. The stock’s 50 day simple moving average is $1.10 and its 200 day simple moving average is $1.34. Brainstorm Cell Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $6.00.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Thursday, May 15th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.07). As a group, analysts anticipate that Brainstorm Cell Therapeutics will post -3.01 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Gunderson Capital Management Inc. purchased a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 25,950 shares of the biotechnology company’s stock, valued at approximately $29,000. Gunderson Capital Management Inc. owned 0.26% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.